Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Adamis Pharmaceuticals Corporation announced a license to commercialize Tempol, a novel patented investigational drug for the treatment of COVID-19. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.
[Adamis Pharmaceuticals]
Press Release
Bookmark

No account yet? Register

0
Share

Wnt/β‐Catenin Signaling Is Critical for Regenerative Potential of Distal Lung Epithelial Progenitor Cells in Homeostasis and Emphysema

Researchers identified an organoid‐forming adult distal lung epithelial progenitor cell population characterized by a low Wnt/β‐catenin activity, which was enriched in club and alveolar epithelial type II cells.
[Stem Cells]
Full Article
Bookmark

No account yet? Register

0
Share

SIRT7‐Mediated Modulation of Glutaminase 1 Regulates TGF‐β‐Induced Pulmonary Fibrosis

Investigators showed that the profibrotic actions of TGF‐β were mediated, at least in part, through a metabolic maladaptation in glutamine metabolism and how the inhibition of glutaminase 1 reversed pulmonary fibrosis.
[FASEB Journal]
Full Article
Bookmark

No account yet? Register

0
Share

Huge Open-Access Journal Deal Inked by University of California and Springer Nature

The University of California (UC) system announced it has signed the biggest open-access deal in North America with one of the largest commercial scientific publishers. The agreement with Springer Nature includes a commitment by the publisher to explore making all articles that UC corresponding authors publish in the Nature family of journals immediately free to read on publication starting in 2022.
[ScienceInsider]
Editorial
Bookmark

No account yet? Register

0
Share

MDL-800, An Allosteric Activator of SIRT6, Suppresses Proliferation and Enhances EGFR-TKIs Therapy in Non-Small Cell Lung Cancer

Scientists investigated whether MDL-800, an allosteric activator of Sirtuin 6, exerted antiproliferation effect against non-small cell lung carcinoma cells in vitro and in vivo.
[Acta Pharmacologica Sinica]
Abstract
Bookmark

No account yet? Register

0
Share

Annexin-A1 Promotes RIG-I-Dependent Signaling and Apoptosis via Regulation of the IRF3–IFNAR–STAT1–IFIT1 Pathway in A549 Lung Epithelial Cells

Researchers explored the role of Annexin A1 (ANXA1) in Influenza Type A viruses infection of A549 lung epithelial cells further in the context of RIG-I-dependent signaling using A549 and Crispr/Cas9 ANXA1 deleted cells
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share

Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells

Scientists identified protein kinase A (PKA) as an active kinase in small cell lung cancer (SCLC). Inhibition of PKA activity genetically, or pharmacologically by activation of the PP2A phosphatase, suppressed SCLC expansion in culture and in vivo.
[Cancer Cell]
Coles, G. L., Cristea, S., Webber, J. T., Levin, R. S., Moss, S. M., He, A., Sangodkar, J., Hwang, Y. C., Arand, J., Drainas, A. P., Mooney, N. A., Demeter, J., Spradlin, J. N., Mauch, B., Le, V., Shue, Y. T., Ko, J. H., Lee, M. C., Kong, C., … Sage, J. (2020). Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell, 0(0). https://doi.org/10.1016/j.ccell.2020.05.003 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Targeting Focal Adhesion Kinase in Cancer Cells and the Tumor Microenvironment

Scientists discuss the role of nuclear focal adhesion kinase (FAK) as a driver for tumor cell survival as well as potential therapeutic strategies to target FAK in both tumors and the tumor microenvironment
[Experimental and Molecular Medicine]
Targeting focal adhesion kinase in cancer cells and the tumor microenvironment | Experimental & Molecular Medicine. (n.d.). Retrieved June 12, 2020, from https://www.nature.com/articles/s12276-020-0447-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Differential Functions of ERK1 and ERK2 in Lung Metastasis Processes in Triple-Negative Breast Cancer

Investigators provided evidence supporting the notion that ERK1 and ERK2 have functionally distinct properties and that ERK2, not ERK1, primarily contributed to lung metastasis in a riple negative breast cancer mouse model.
[Scientific Reports]
Abstract
Bookmark

No account yet? Register

0
Share
Share